TLR5 and colorectal neoplasm: While further work with TLR5 expressing and non-expressing tumors will characterize their sensitivity and vulnerability to TNF and ensure that entolimod’s protective effect is selective for normal cells, this study provides the first evidence of such selectivity using TLR5 non-responsive hepatocellular and colorectal tumor models.